Blood test may help tailor chemo for colorectal cancer patients

NCT ID NCT07562659

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with stage I or low-risk stage II colorectal cancer who have a positive ctDNA blood test one month after surgery, indicating a higher risk of recurrence. Researchers will assign different chemotherapy regimens based on ctDNA results to see if this personalized approach can clear the cancer DNA from the blood and improve survival. The trial aims to find better ways to prevent cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine, FOLFOX, CAPOX, FOLFIRI, CAPEIRI (chemotherapy drugs)
What this could lead to: If successful, this approach could help doctors choose the right chemotherapy for each patient, potentially reducing the chance of cancer coming back.
What could go wrong: This is a small, early-phase trial with only 80 participants, so results may not apply to everyone. Chemotherapy can cause side effects like fatigue, nausea, and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT CHEMOTHERAPY COLORECTAL CANCER (CRC) CTDNA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.